Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.
Immunotherapy
Melanoma brain metastasis
Perilesional edema
Radio-surgery
Stereotactic radiotherapy
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
09
08
2024
accepted:
30
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
Stereotactic radiotherapy (SRT) is an established treatment for melanoma brain metastases (MBM). Recent evidence suggests that perilesional edema volume (PEV) might compromise the delivery and efficacy of radiotherapy to treat BM. This study investigated the association between SRT efficacy and PEV extent in MBM. This retrospective study reviewed medical records from January 2020 to September 2023. Patients with up to 5 measurable MBMs, intracranial disease per RANO/iRANO criteria, and on low-dose corticosteroids were included. MRI scans assessed baseline neuroimaging, with PEV analyzed using 3D Slicer. SRT plans were based on MRI-CT fusion, delivering 18-32.5 Gy in 1-5 fractions. Outcomes included intracranial objective response rate (iORR) and survival measures (L-iPFS and OS). Statistical analysis involved decision tree analysis and multivariable logistic regression, adjusting for clinical and treatment variables. Seventy-two patients with 101 MBM were analyzed, with a mean age of 68.83 years. The iORR was 61.4%, with Complete Response (CR) in 21.8% and Partial Response (PR) in 39.6% of the treated lesions. PEV correlated with KPS, BRAF status, and treatment response. Decision tree analysis identified a PEV cutoff at 0.5 cc, with lower PEVs predicting better responses (AUC = 0.82 sensitivity: 86.7%, specificity:74.4%,). Patients with PEV ≥ 0.5 cc had lower response rates (iORR 44.7% vs. 63.8%, p < 0.001). Median OS was 9.4 months, with L-iPFS of 27 months. PEV significantly impacted survival outcomes. A more extensive PEV was associated with a less favorable outcome to SRT in MBM.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Stereotactic radiotherapy (SRT) is an established treatment for melanoma brain metastases (MBM). Recent evidence suggests that perilesional edema volume (PEV) might compromise the delivery and efficacy of radiotherapy to treat BM. This study investigated the association between SRT efficacy and PEV extent in MBM.
MATERIALS AND METHODS
METHODS
This retrospective study reviewed medical records from January 2020 to September 2023. Patients with up to 5 measurable MBMs, intracranial disease per RANO/iRANO criteria, and on low-dose corticosteroids were included. MRI scans assessed baseline neuroimaging, with PEV analyzed using 3D Slicer. SRT plans were based on MRI-CT fusion, delivering 18-32.5 Gy in 1-5 fractions. Outcomes included intracranial objective response rate (iORR) and survival measures (L-iPFS and OS). Statistical analysis involved decision tree analysis and multivariable logistic regression, adjusting for clinical and treatment variables.
RESULTS
RESULTS
Seventy-two patients with 101 MBM were analyzed, with a mean age of 68.83 years. The iORR was 61.4%, with Complete Response (CR) in 21.8% and Partial Response (PR) in 39.6% of the treated lesions. PEV correlated with KPS, BRAF status, and treatment response. Decision tree analysis identified a PEV cutoff at 0.5 cc, with lower PEVs predicting better responses (AUC = 0.82 sensitivity: 86.7%, specificity:74.4%,). Patients with PEV ≥ 0.5 cc had lower response rates (iORR 44.7% vs. 63.8%, p < 0.001). Median OS was 9.4 months, with L-iPFS of 27 months. PEV significantly impacted survival outcomes.
CONCLUSIONS
CONCLUSIONS
A more extensive PEV was associated with a less favorable outcome to SRT in MBM.
Identifiants
pubmed: 39259411
doi: 10.1007/s11060-024-04818-9
pii: 10.1007/s11060-024-04818-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Gritsko VM et al (2009) Brain metastases in melanoma patients: prevalence, management, and outcomes. Cancer. 115(23):5353–5361
Dai C et al (2015) Increasing incidence of brain metastases in melanoma patients: implications for treatment strategies. Melanoma Research. 25(2):125–130
Lin JJ et al (2021) Brain metastases in melanoma: current management and emerging therapies. Curr Oncol Rep 23(7):1–11
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol.;40(5):492–516. https://doi.org/10.1200/JCO.21.02314 . Epub 2021 Dec 21. Erratum in: J Clin Oncol. 2022;40(12):1392. doi: 10.1200/JCO.22.00593. PMID: 34932393
Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. https://doi.org/10.1186/1748-717X-6-48 PMID: 21575163; PMCID: PMC3108308
doi: 10.1186/1748-717X-6-48
pubmed: 21575163
pmcid: 3108308
Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97(3):377–381 Epub 2010 Sep 18. PMID: 20855119
doi: 10.1016/j.radonc.2010.08.020
pubmed: 20855119
Sayan M, Zoto Mustafayev T, Sahin B, Kefelioglu ESS, Wang SJ, Kurup V, Balmuk A, Gungor G, Ohri N, Weiner J, Ozyar E, Atalar B (2019) Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases. Radiat Oncol J 37(4):265–270 Epub 2019 Dec 31. PMID: 31918464; PMCID: PMC6952719
doi: 10.3857/roj.2019.00409
pubmed: 31918464
pmcid: 6952719
Petrelli F, De Stefani A, Trevisan F, Parati C, Inno A, Merelli B, Ghidini M, Bruschieri L, Vitali E, Cabiddu M, Borgonovo K, Ghilardi M, Barni S, Ghidini A (2019) Combination of radiotherapy and immunotherapy for brain metastases: a systematic review and meta-analysis. Crit Rev Oncol Hematol 144:102830 Epub 2019 Nov 1. PMID: 31733443
doi: 10.1016/j.critrevonc.2019.102830
pubmed: 31733443
Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Quiñones-Hinojosa A, Zaorsky NG, Trifiletti DM (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104–112 Epub 2018 Sep 18. PMID: 30241791
doi: 10.1016/j.radonc.2018.08.025
pubmed: 30241791
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL (2016). Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. doi: https://doi.org/10.1001/jama.2016.9839 . Erratum in: JAMA. 2018;320(5):510. doi: 10.1001/jama.2018.9890. PMID: 27458945; PMCID: PMC5313044.
Moraes FY, Taunk NK, Marta GN, Suh JH, Yamada Y (2016) The rationale for targeted therapies and stereotactic radiosurgery in the treatment of Brain metastases. Oncologist 21(2):244–251. https://doi.org/10.1634/theoncologist.2015-0293 Epub 2016 Jan 13. PMID: 26764249; PMCID: PMC4746085
doi: 10.1634/theoncologist.2015-0293
pubmed: 26764249
pmcid: 4746085
He Q, Zhang C, Tang S, Li J, Ren Q (2020;) Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis. Transl Cancer Res 9(10):5909–5924. https://doi.org/10.21037/tcr-20-902 . PMID: 35117204; PMCID: PMC8797322
Kim JH, Jenrow KA, Brown SL (2018) Novel biological strategies to enhance the radiation therapeutic ratio. Radiat Oncol J 36(3):172–181. https://doi.org/10.3857/roj.2018.00332 Epub 2018 Sep 30. PMID: 30309208; PMCID: PMC6226138
doi: 10.3857/roj.2018.00332
pubmed: 30309208
pmcid: 6226138
Marampon F, Gelibter AJ, Cicco PR, Parisi M, Serpone M, De Felice F, Bulzonetti N, Musio D, Cortesi E, Tombolini V (2022) Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review. BJR Case Rep 8(5):20200134. https://doi.org/10.1259/bjrcr.20200134 PMID: 36211614; PMCID: PMC9518736
doi: 10.1259/bjrcr.20200134
pubmed: 36211614
pmcid: 9518736
Guénolé M, Lucia F, Bourbonne V, Dissaux G, Reygagne E, Goasduff G, Pradier O, Schick U (2020) Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases. BMC Cancer 20(1):991. https://doi.org/10.1186/s12885-020-07491-z PMID: 33050910; PMCID: PMC7557085
doi: 10.1186/s12885-020-07491-z
pubmed: 33050910
pmcid: 7557085
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA.;316(4):401–409. https://doi.org/10.1001/jama.2016.9839 . Erratum in: JAMA. 2018;320(5):510. doi: 10.1001/jama.2018.9890. PMID: 27458945; PMCID: PMC5313044
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol.;18(8):1049–1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4. PMID: 28687377; PMCID: PMC5568757
Simonsen MK, Vrou Offersen B, Jensen AB (2023) Prognosis of breast cancer patients with brain metastasis treated with radiotherapy. Acta Oncol 62(8):871–879 Epub 2023 Jul 27. PMID: 37498539
doi: 10.1080/0284186X.2023.2238551
pubmed: 37498539
Franceschini D, De Rose F, Franzese C, Comito T, Di Brina L, Radicioni G, Evangelista A, D’Agostino GR, Navarria P, Scorsetti M (2019) Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body Radiation Therapy. Int J Radiat Oncol Biol Phys 104(1):111–121 Epub 2019 Jan 8. PMID: 30630030
doi: 10.1016/j.ijrobp.2018.12.049
pubmed: 30630030
Amsbaugh MJ, Yusuf MB, Gaskins J, Dragun AE, Dunlap N, Guan T, Woo SA, Dose-Volume (2017) Response model for brain metastases treated with Frameless single-fraction robotic radiosurgery: seeking to Better Predict response to treatment. Technol Cancer Res Treat 16(3):344–351 Epub 2016 Dec 27. PMID: 28027696; PMCID: PMC5616050
Jaberipour M, Soliman H, Sahgal A, Sadeghi-Naini A (2021) A priori prediction of local failure in brain metastasis after hypo-fractionated stereotactic radiotherapy using quantitative MRI and machine learning. Sci Rep 11(1):21620. https://doi.org/10.1038/s41598-021-01024-9 PMID: 34732781; PMCID: PMC8566533
doi: 10.1038/s41598-021-01024-9
pubmed: 34732781
pmcid: 8566533
Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol.;75(1):5–14. https://doi.org/10.1007/s11060-004-8093-6 . PMID: 16215811
Kerschbaumer J, Bauer M, Popovscaia M, Grams AE, Thomé C, Freyschlag CF (2017) Correlation of Tumor and Peritumoral Edema Volumes with Survival in Patients with Cerebral Metastases. Anticancer Res.;37(2):871–875. https://doi.org/10.21873/anticanres.11392 . PMID: 28179345
Chang EL, Akyurek S, Avalos T, Rebueno N, Spicer C, Garcia J, Famiglietti R, Allen PK, Chao KS, Mahajan A, Woo SY, Maor MH (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys.;68(1):144– 50. doi: 10.1016/j.ijrobp.2006.12.009. Epub 2007 Feb 15. PMID: 17306935
Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Marosi C, Birner P, Prayer D, Preusser M (2013) Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis 30(4):357–368. https://doi.org/10.1007/s10585-012-9542-9 Epub 2012 Oct 17. PMID: 23076770
doi: 10.1007/s10585-012-9542-9
pubmed: 23076770
Tini P, Nardone V, Pastina P, Battaglia G, Vinciguerra C, Carfagno T, Rubino G, Carbone SF, Sebaste L, Cerase A, Federico A, Pirtoli L (2017) Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS). Neurol Sci.;38(6):975–982. https://doi.org/10.1007/s10072-017-2876-y . Epub 2017 Mar 4. PMID: 28260188
Nardone V, Nanni S, Pastina P, Vinciguerra C, Cerase A, Correale P, Guida C, Giordano A, Tini P, Reginelli A, Cappabianca S, Pirtoli L (2019) Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases. Strahlenther Onkol 195(8):734–744 English. doi:. https://doi.org/10.1007/s00066-019-01475-0
doi: 10.1007/s00066-019-01475-0
pubmed: 31123785
Arrieta O, Bolaño-Guerra LM, Caballé-Pérez E, Lara-Mejía L, Turcott JG, Gutiérrez S, Lozano-Ruiz F, Cabrera-Miranda L, Arroyave-Ramírez AM, Maldonado-Magos F, Corrales L, Martín C, Gómez-García AP, Cacho-Díaz B, Cardona AF (2023) Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer. Front Oncol 13:1251620. https://doi.org/10.3389/fonc.2023.1251620 PMID: 37916162; PMCID: PMC10616784
doi: 10.3389/fonc.2023.1251620
pubmed: 37916162
pmcid: 10616784
Alemany M, Domènech M, Argyriou AA, Vilariño N, Majós C, Naval-Baudin P, Lucas A, Palmero R, Simó M, Nadal E, Bruna J (2021) Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. Ann Transl Med 9(8):648. https://doi.org/10.21037/atm-20-6497 PMID: 33987346; PMCID: PMC8106019
doi: 10.21037/atm-20-6497
pubmed: 33987346
pmcid: 8106019
Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY (2015) Response Assessment in Neuro-Oncology (RANO) group. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol.;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27. PMID: 26065612
Talbot D, Massamba VK (2019) A descriptive review of variable selection methods in four epidemiologic journals: there is still room for improvement. Eur J Epidemiol.;34(8):725–730. https://doi.org/10.1007/s10654-019-00529-y . Epub 2019 Jun 3. PMID: 31161279
Singh K, Saxena S, Khosla AA, McDermott MW, Kotecha RR, Ahluwalia MS (2022) Update on the management of Brain Metastasis. Neurotherapeutics 19(6):1772–1781. https://doi.org/10.1007/s13311-022-01312-w Epub 2022 Nov 23. PMID: 36422836; PMCID: PMC9723062
doi: 10.1007/s13311-022-01312-w
pubmed: 36422836
pmcid: 9723062
Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer.;2(1):38–47. https://doi.org/10.1038/nrc704 . PMID: 11902584
Tang M, Bolderson E, O’Byrne KJ, Richard DJ (2021) Tumor Hypoxia drives genomic instability. Front Cell Dev Biol 9:626229. https://doi.org/10.3389/fcell.2021.626229 PMID: 33796526; PMCID: PMC8007910
doi: 10.3389/fcell.2021.626229
pubmed: 33796526
pmcid: 8007910
Zhu P, He F, Hou Y, Tu G, Li Q, Jin T, Zeng H, Qin Y, Wan X, Qiao Y, Qiu Y, Teng Y, Liu M (2021) A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability. Oncogene 40(9):1609–1627. https://doi.org/10.1038/s41388-020-01638-9 Epub 2021 Jan 19. PMID: 33469161; PMCID: PMC7932928
doi: 10.1038/s41388-020-01638-9
pubmed: 33469161
pmcid: 7932928
Lendeckel U, Wolke C (2022) Redox-Regulation in Cancer Stem cells. Biomedicines 10(10):2413. https://doi.org/10.3390/biomedicines10102413 PMID: 36289675; PMCID: PMC9598867
doi: 10.3390/biomedicines10102413
pubmed: 36289675
pmcid: 9598867
Viallard C, Larrivée B (2017) Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20(4):409–426. https://doi.org/10.1007/s10456-017-9562-9 Epub 2017 Jun 28. PMID: 28660302
doi: 10.1007/s10456-017-9562-9
pubmed: 28660302
Zheng R, Li F, Li F, Gong A (2021) Targeting tumor vascularization: promising strategies for vascular normalization. J Cancer Res Clin Oncol 147(9):2489–2505. https://doi.org/10.1007/s00432-021-03701-8 Epub 2021 Jun 19. PMID: 34148156
doi: 10.1007/s00432-021-03701-8
pubmed: 34148156
Choi Y, Jung K (2023) Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med 55(11):2308–2319. https://doi.org/10.1038/s12276-023-01114-w Epub 2023 Nov 1. PMID: 37907742; PMCID: PMC10689787
doi: 10.1038/s12276-023-01114-w
pubmed: 37907742
pmcid: 10689787